All News

Found 5,918 articles

• Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

  11/16/2023

  Antengene Corporation Limited ("Antengene" SEHK: 6996.HK) is presenting encouraging clinical data of the Company's four key drugs in clinical development: ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-037 (oral CD73 inhibitor), and ATG-008 (dual mTORC1/2 inhibitor), at its 2023 R&D Day taking place today.

• Autonomix Medical, Inc. Announces Appointment of Christopher C. Capelli, M.D. to Board of Directors

  11/16/2023

  Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Christopher C. Capelli, M.D. to its Board of Directors.

• Proxygen Announces Formation of Scientific Advisory Board

  11/15/2023

  Proxygen, a leader in the discovery and development of molecular glue degraders, announced the formation of the company’s scientific advisory board.

• Bio-Path Holdings Reports Third Quarter 2023 Financial Results

  11/15/2023

  Bio-Path Holdings, Inc. announced its financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.

• Tessellate BIO, an Emerging Precision Oncology Company, Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board

  11/15/2023

  Tessellate BIO announces the appointment of multiple international experts to its Scientific Advisory Board.

• Bionano Announces Presentation of OGM Utility Across Key Research Applications at the Association for Molecular Pathology Annual Meeting

  11/14/2023

  Bionano Genomics, Inc. announced its participation in the Association for Molecular Pathology 2023 Annual Meeting and Expo with a broad range of content covering the utility of optical genome mapping for cell and gene therapy and cancer research, including scientific workshops and poster presentations from Bionano and researchers from across the genomics landscape.

• Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

  11/14/2023

  Affimed N.V. reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.

• IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update

  11/14/2023

  IMUNON, Inc. announced financial results for the three and nine months ended September 30, 2023.

• Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

  11/14/2023

  Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023.

• LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

  11/13/2023

  LIXTE Biotechnology Holdings, Inc. chemotherapy and immunotherapy benefit, today provided an update on its progress.

• NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

  11/13/2023

  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the third quarter of 2023.

• XNK Therapeutics to present at Investival Showcase Meeting - November 10, 2023

  11/10/2023

  XNK Therapeutics AB announced that Johan Liwing, CEO, will present the company at the at Investival Showcase Meeting in London, on November 13th

• Cantargia Publishes Interim Report for Third Quarter 2023

  11/10/2023

  Cantargia Cantargia AB's interim report for the period January until September 2023 is now available on the company's web page

• March Biosciences and Cancer Focus Fund Announce $4.8 Million Investment to Support a Phase 2 Clinical Trial of Novel CAR-T Therapy for T-Cell Lymphoma

  11/9/2023

  March Biosciences and Cancer Focus Fund, LP announced that Cancer Focus Fund is investing $4.8 million in funding and providing clinical support for March Bio's upcoming Phase 2 clinical trial of MB-105 for the treatment of relapsed T-cell leukemias and lymphomas.

• Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

  11/9/2023

  Affimed N.V. announced that the International Nonproprietary Names Expert Committee of the World Health Organization has selected "acimtamig" for the nonproprietary name of the Company’s investigational drug for CD30-positive Lymphomas, previously known as AFM13.

• Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

  11/9/2023

  Aprea Therapeutics, Inc. reported financial results for the three and nine months ended September 30, 2023, and provided a business update.

• Aptose Reports Results for the Third Quarter 2023

  11/9/2023

  Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced financial results for the three months and nine months ended September 30, 2023, and provided a corporate update.

• Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

  11/9/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2023, and highlighted recent business updates.

• American Brain Tumor Association Announces $1.3 Million in New Funding to Accelerate Adult and Pediatric Brain Tumor Research

  11/8/2023

  The American Brain Tumor Association announced the funding of $1.37 million towards 23 new research grants to advance brain tumor science and treatments, across all brain tumor types and ages.

• bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy

  11/8/2023

  bit.bio, the company coding human cells for novel cures, announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter clinical development in 2025.